Skip to main content

Advertisement

SpringerLink
Log in

Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

Meningiomas are generally benign and in most cases surgery is curative. However, for high-grade histotypes or partially resected tumours, recurrence is fairly common. External beam radiation therapy (EBRT) is usually given in such cases but is not always effective. We assessed peptide receptor radionuclide therapy (PRRT) using 90Y-DOTATOC in a group of patients with meningioma recurring after standard treatments in all of whom somatostatin receptors were strongly expressed on meningioma cell surfaces.

Methods

Twenty-nine patients with scintigraphically proven somatostatin subtype 2 receptor-positive meningiomas were enrolled: 14 had benign (grade I), 9 had atypical (grade II) and 6 had malignant (grade III) disease. Patients received intravenous 90Y-DOTATOC for 2–6 cycles for a cumulative dose in the range of 5–15 GBq. Clinical and neuroradiological evaluations were performed at baseline, during and after PRRT.

Results

The treatment was well tolerated in all patients. MRI 3 months after treatment completion showed disease stabilization in 19 of 29 patients (66%) and progressive disease in the remaining 10 (34%). Better results were obtained in patients with grade I meningioma than in those with grade II–III, with median time to progression (from beginning PRRT) of 61 months in the low-grade group and 13 months in the high-grade group.

Conclusion

PRRT with 90Y-DOTATOC can interfere with the growth of meningiomas. The adjuvant role of this treatment, soon after surgery, especially in atypical and malignant histotypes, deserves further investigation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Black P. Meningiomas. In: Black P, Loeffler JS, editors. Cancer of the nervous system. Oxford UK: Blackwell Science; 1997. p. 349–62.

    Google Scholar 

  2. Russel D, Rubinstein L. Tumours of the meninges and related tissues. In: Russel D, Rubinstein L, editors. Pathology of tumours of the nervous system. Baltimore: Williams and Wilkins; 1989. p. 449–532.

    Google Scholar 

  3. Rachlin J, Rosenblum M. Etiology and biology of meningiomas. In: Al-Mefty O, editor. Meningiomas. New York: Raven; 1991. p. 22–37.

    Google Scholar 

  4. Drake J, Hoffman H. Meningiomas in children. In: Al-Mefty O, editor. Meningiomas. New York: Raven; 1991. p. 145–52.

    Google Scholar 

  5. Butti G, Assietti R, Casalone R, Paoletti P. Multiple meningiomas: a clinical, surgical and cytogenetic analysis. Surg Neurol 1989;31:255–60.

    Article  PubMed  CAS  Google Scholar 

  6. Modan B, Baidatz D, Mart H, Steinitz R, Levin SG. Radiation-induced head and neck tumours. Lancet 1974;1:277–79.

    Article  PubMed  CAS  Google Scholar 

  7. Balasubramaniam C, Armstrong D, Cheek W, Laurent J. Postradiation meningiomas in a child. Pediatr Neurosci 1988;14(3):319–23.

    Article  PubMed  CAS  Google Scholar 

  8. Mark J, Levan G, Mitelman F. Identification by fluorescence of the G chromosome lost in human meningiomas. Hereditas 1972;71:163–8.

    PubMed  CAS  Google Scholar 

  9. Zankl H, Zang KD. Cytological and cytogenetical studies on brain tumors. 4. Identification of the missing G chromosome in human meningiomas as no. 22 by fluorescence technique. Humangenetik 1972;14(2):167–9.

    Article  PubMed  CAS  Google Scholar 

  10. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002;61(3):215–29.

    PubMed  Google Scholar 

  11. Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry 1957;20:22–39.

    Article  PubMed  CAS  Google Scholar 

  12. Marimanoff RO, Dosoretz DE, Linggood RM, Ojemann RG, Martuzza RL. Meningioma: analysis of recurrence and progression after neurosurgical resection. J Neurosurg 1985;62:18–24.

    Article  Google Scholar 

  13. Jaaskelainen J, Haltia M, Servo A. Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome. Surg Neurol 1986;25:233–42.

    Article  PubMed  CAS  Google Scholar 

  14. Taylor BW Jr, Marcus RB Jr, Friedman WA, Ballinger WE Jr, Million RR. The meningioma controversy: postoperative radiation therapy. Int J Radiat Oncol Biol Phys 1988;15:299–304.

    Article  PubMed  Google Scholar 

  15. Condra KS, Buatti JM, Mendenhall WM, Friedman WA, Marcus RB Jr, Rhoton AL. Benign meningiomas: primary treatment selection affects survival. Int J Radiat Oncol Biol Phys 1997;39(2):427–36.

    PubMed  CAS  Google Scholar 

  16. Mesic JB, Hanks GE, Doggett RL. The value of radiation therapy as an adjuvant to surgery in intracranial meningiomas. Am J Clin Oncol 1986;9(4):337–40.

    Article  PubMed  CAS  Google Scholar 

  17. Dziuk TW, Woo S, Butler EB, Thornby J, Grossman R, Dennis WS, et al. Malignant meningioma: an indication for initial aggressive surgery and adjuvant radiotherapy. J Neurooncol 1998;37(2):177–88.

    Article  PubMed  CAS  Google Scholar 

  18. Chan RC, Thompson GB. Morbidity, mortality, and quality of life following surgery for intracranial meningiomas. A retrospective study in 257 cases. J Neurosurg 1984;60:52–60.

    Article  PubMed  CAS  Google Scholar 

  19. Goldsmith BJ, Wara WM, Wilson CB, Larson DA. Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990. J Neurosurg 1994;80:195–201. Erratum in: J Neurosurg 1994;80:777.

    Article  PubMed  CAS  Google Scholar 

  20. Wen PY, Drappatz J. Novel therapies for meningiomas. Expert Rev Neurother 2006;6(10):1447–64.

    Article  PubMed  CAS  Google Scholar 

  21. Pravdenkova S, Al-Mefty O, Sawyer J, Husain M. Progesterone and estrogen receptors: opposing prognostic indicators in meningiomas. J Neurosurg 2006;105(2):163–73.

    Article  PubMed  CAS  Google Scholar 

  22. Black PM. Hormones, radiosurgery and virtual reality: new aspects of meningioma management. Can J Neurol Sci 1997;24(4):302–6.

    PubMed  CAS  Google Scholar 

  23. Reubi JC, Krenning EP, Lamberts SW, Kvols L. In vitro detection of receptors in human tumours. Digestion 1993;54(Suppl 1):76–83.

    Article  PubMed  Google Scholar 

  24. De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, et al. Somatostatin receptor-targeted radionuclide therapy of tumours: preclinical and clinical findings. Semin Nucl Med 2002;32(2):133–40.

    Article  PubMed  Google Scholar 

  25. Reubi JC, Maurer R, Klijn JG, Stefanko SZ, Foekens JA, Blaauw G, et al. High incidence of somatostatin receptors in human meningiomas: biochemical characterization. J Clin Endocrinol Metab 1986;63:433–8.

    Article  PubMed  CAS  Google Scholar 

  26. de Herder WW, Kwekkeboom DJ, Valkema R, Feelders RA, van Aken MO, Lamberts SW, et al. Neuroendocrine tumors and somatostatin: imaging techniques. J Endocrinol Invest 2005;28(11 Suppl International):132–6.

    PubMed  Google Scholar 

  27. van Essen M, Krenning EP, De Jong M, Valkema R, Kwekkeboom DJ. Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol 2007;46(6):723–34.

    Article  PubMed  CAS  Google Scholar 

  28. Esser JP, Krenning EP, Teunissen JJ, Kooij PP, van Gameren AL, Bakker WH, et al. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT? Eur J Nucl Med Mol Imaging 2006;33(11):1346–51.

    Article  PubMed  CAS  Google Scholar 

  29. Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23(12):2754–62.

    Article  PubMed  CAS  Google Scholar 

  30. Bodei L, Cremonesi M, Grana C, Rocca P, Bartolomei M, Chinol M, et al. Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004;31(7):1038–46.

    Article  PubMed  CAS  Google Scholar 

  31. Paganelli G, Bodei L, Handkiewicz Junak D, Rocca P, Papi S, Lopera Sierra M, et al. 90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies. Biopolymers 2002;66(6):393–8.

    Article  PubMed  CAS  Google Scholar 

  32. Paganelli G, Zoboli S, Cremonesi M, Bodei L, Ferrari M, Grana C, et al. Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide. Eur J Nucl Med 2001;28(4):426–34.

    Article  PubMed  CAS  Google Scholar 

  33. Bodei L, Handkiewicz-Junak D, Grana C, Mazzetta C, Rocca P, Bartolomei M, et al. Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas. Cancer Biother Radiopharm 2004;19(1):65–71.

    Article  PubMed  CAS  Google Scholar 

  34. Chinol M, Bodei L, Cremonesi M, Paganelli G. Receptor-mediated radiotherapy with 90Y-DOTA-DPhe1-Tyr3-octreotide: the experience of the European Institute of Oncology Group. Semin Nucl Med 2002;32(2):141–7.

    Article  PubMed  Google Scholar 

  35. Bodei L, Cremonesi M, Zoboli S, Grana C, Bartolomei M, Rocca P, et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging 2003;30(2):207–16.

    PubMed  CAS  Google Scholar 

  36. WHO handbook for reporting results of cancer treatment. Geneva, Switzerland: World Health Organization Offset Publication; 1979. p. 48.

  37. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992;10:239–53.

    Article  PubMed  CAS  Google Scholar 

  38. Grunberg SM, Weiss MH, Spitz IM, Ahmadi J, Sadun A, Russell CA, et al. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg 1991;74(6):861–6.

    Article  PubMed  CAS  Google Scholar 

  39. Grumberg SM, Rankin C, Townsend J, Ahmadi J, Feun L, Fredericks R, et al. Phase III double-blind randomized placebo controlled study of mifepristone (RU) for the treatment of unresectable meningioma. ASCO 2001 Proceedings 20:56a.

  40. Klutmann S, Bohuslavizki KH, Brenner W, Behnke A, Tietje N, Kröger S, et al. Somatostatin receptor scintigraphy in postsurgical follow-up examinations of meningioma. J Nucl Med 1998;39:1913–17.

    PubMed  CAS  Google Scholar 

  41. Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss LG, Doll J, et al. Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. J Nucl Med 2005;46(5):763–9.

    PubMed  CAS  Google Scholar 

  42. Gay E, Vuillez JP, Palombi O, Brard PY, Bessou P, Passagia JG. Intraoperative and postoperative gamma detection of somatostatin receptors in bone-invasive en plaque meningiomas. Neurosurgery 2005;57(1 Suppl):107–13.

    Article  PubMed  Google Scholar 

  43. Chamberlain MC, Glantz MJ, Fadul CE. Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology 2007;69(10):969–73.

    Article  PubMed  CAS  Google Scholar 

  44. Koper JW, Markstein R, Kohler C, Kwekkeboon DJ, Avezaat CJ, Lamberts SW, et al. Somatostatin inhibits the activity of adenylate cyclase in cultured human meningioma cells and stimulates their growth. J Clin Endocrinol Metab 1992;74(3):543–7.

    Article  PubMed  CAS  Google Scholar 

  45. Ko KW, Nam DH, Kong DS, Lee JI, Park K, Kim JH. Relationship between malignant subtypes of meningioma and clinical outcome. J Clin Neurosci 2007;14(8):747–53.

    Article  PubMed  Google Scholar 

  46. Modha A, Gutin PH. Diagnosis and treatment of atypical and anaplastic meningiomas: a review. Neurosurgery 2005;57(3):538–50.

    Article  PubMed  Google Scholar 

  47. Ho DM, Hsu CY, Ting LT, Chiang H. Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma. Cancer 2002;94(5):1538–47.

    Article  PubMed  Google Scholar 

  48. Brans B, Bodei L, Giammarile F, Linden O, Luster M, Oyen WJ, Tennvall J. Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray". Eur J Nucl Med Mol Imaging 2007;34(5):772–86.

    Article  PubMed  CAS  Google Scholar 

  49. Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med 2006;47(9):1467–75.

    PubMed  CAS  Google Scholar 

  50. van Essen M, Krenning EP, Kooij PP, Bakker WH, Feelders RA, de Herder WW, et al. Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med 2006;47(10):1599–606.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nuclear Medicine, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy

    Mirco Bartolomei, Lisa Bodei, Concetta De Cicco, Chiara Maria Grana, Silvia Melania Baio, Demetrio Aricò & Giovanni Paganelli

  2. Division of Medical Physics, European Institute of Oncology, Milan, Italy

    Marta Cremonesi

  3. Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy

    Edoardo Botteri

  4. Radiometabolic Medicine Division, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola (FC), Italy

    Maddalena Sansovini

Authors
  1. Mirco Bartolomei
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lisa Bodei
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Concetta De Cicco
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chiara Maria Grana
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marta Cremonesi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Edoardo Botteri
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Silvia Melania Baio
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Demetrio Aricò
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Maddalena Sansovini
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Giovanni Paganelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giovanni Paganelli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bartolomei, M., Bodei, L., De Cicco, C. et al. Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma. Eur J Nucl Med Mol Imaging 36, 1407–1416 (2009). https://doi.org/10.1007/s00259-009-1115-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-009-1115-z

Keywords

Search

Navigation